The deal brings AstraZeneca’s total commitment to the biopharmaceutical company to $261 million, as it follows an $87 million deal announced June 11, in which Emergent agreed to become a manufacturing partner for the vaccine. Production activities outlined within the latest deal will take place at Emergent’s Baltimore Bayview facility.
The vaccine candidate, named AZD1222, is being developed in partnership with Oxford University. Early trials for AZD1222 produced two kinds of immune responses that could protect the body against COVID-19, according to research published July 20 in The Lancet.
More articles on pharmacy:
Walgreens CEO steps down
Trump signs 4 executive orders targeting drug prices: 6 things to know
6 pharmacy leaders discuss how the pandemic has affected medication adherence
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
